Drugs / rizatriptan
rizatriptan
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00604812 | Dec 2007 → Sep 2010 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02447991 | Dec 2014 → Jul 2020 | migraine disorder | Robert W. Baloh | Completed | No outcome recorded |
| Phase 321 trials | ||||||
| Phase 3 | NCT04384367 | Dec 2022 → Oct 2024 | migraine disorder | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT05550207 | Aug 2022 → Nov 2024 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04163185 | Oct 2019 → Mar 2020 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04068051 | Jul 2019 → Sep 2020 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01004263 | Dec 2009 → Apr 2011 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01001234 | Nov 2009 → Apr 2011 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00894556 | Jun 2009 → Jan 2010 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00812006 | Mar → Oct 2009 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00516737 | Oct 2007 → Apr 2008 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00471952 | Apr 2007 → Feb 2008 | migraine with aura, migraine without aura | Diamond Headache Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00250458 | Mar → Oct 2006 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00300924 | Mar 2006 → Jan 2007 | migraine disorder | Diamond Headache Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00111709 | May 2005 → Feb 2006 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00111722 | May 2005 → Feb 2006 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00095004 | Oct 2004 → Apr 2005 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092963 | Aug 2004 → Jan 2005 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00898677 | Sep 1995 → May 1996 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00897104 | Aug 1995 → May 1996 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00899379 | Apr 1995 → Jan 1996 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT01286207 | Mar 1995 → May 1997 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00897949 | Mar 1995 → Jan 1996 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01057160 | May 2008 → Jun 2010 | migraine disorder | University of Duisburg-Essen | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00360282 | Aug 2006 → Jan 2009 | migraine disorder | University of Pittsburgh | Completed | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00246337 Comparator | Nov 2005 → May 2006 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03896009 Comparator | Mar → Dec 2019 | migraine disorder | Axsome Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00443209 Comparator | Feb 2007 → Jan 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT01086358 Comparator | Sep 2009 → Aug 2016 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00753311 Comparator | Jul 2009 → Nov 2010 | migraine disorder | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 4 | NCT00397254 Comparator | Dec 2006 → Jan 2008 | migraine disorder | Clinvest | Completed | No outcome recorded |
| Phase 4 | NCT00910689 Comparator | Jul 2001 → Nov 2005 | migraine disorder | Ohio University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01306266 Comparator | Feb → Aug 2011 | — | Henry M. Jackson Foundation for the Advancement of Military Medicine | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-04-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Generic Maxalt® Tablets tevapharm.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rizatriptan | “The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or...” NCT00910689 ↗33“The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine.” NCT00471952 ↗ “Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan” NCT01086358 ↗ “AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.” NCT04068051 ↗ “migraine (sumatriptan, rizatriptan, zolmitriptan)” NCT02670161 ↗ |
| Known as | MAXALT | “Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence.” PMID 9595867 ↗ Apr 1998 |
| Known as | MK0462 | “Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate” NCT00250458 ↗5“MK0462, rizatriptan benzoate / Duration of Treatment -1 day” NCT00111709 ↗ “MK0462, rizatriptan benzoate / Duration of Treatment: 1day” NCT00095004 ↗ “MK0462, rizatriptan benzoate / Duration of Treatment -1day” NCT00111722 ↗ “MK0462, rizatriptan benzoate / Duration of Treatment: 1day” NCT00092963 ↗ “rizatriptan benzoate (MK0462)” NCT00897949 ↗ |
| Known as | rizatriptan benzoate | “MK0462, rizatriptan benzoate / Duration of Treatment -1 day” NCT00111709 ↗5“MK0462, rizatriptan benzoate / Duration of Treatment -1day” NCT00111722 ↗ “MK0462, rizatriptan benzoate / Duration of Treatment: 1day” NCT00095004 ↗ “MK0462, rizatriptan benzoate / Duration of Treatment: 1day” NCT00092963 ↗ “rizatriptan benzoate (MK0462)” NCT00897949 ↗ “rizatriptan benzoate (MK0462)” NCT00897104 ↗ |
| Action | Activate | “Rizatriptan is a novel 5-HT1B/1D agonist” PMID 9595867 ↗ Apr 1998 |
| Route | Oral | “Rizatriptan 10 mg; one orally-administered dose” NCT00246337 ↗ |